Michelle L. Ray

TL;DR: An ultra-sensitive liquid chromatography tandem mass spectrometry (LC-MS/MS) assay was developed and validated to facilitate the assessment of clinical pharmacokinetics of nucleotide analogs from lysed intracellular matrix and was successfully applied to clinical research samples generating novel intrACEllular information for TFV, FTC, ZDV, and 3TC nucleotides.

TL;DR: An LC-MS-MS methodology was developed and validated for the determination of TFV concentrations, which directly correspond with the intra-hPBMC TFV-DP concentration, and was linear in the range of 50-10,000 fmol per sample.

TL;DR: YP3A5 expressors had faster atazanavir CL/F and lower C(min) than non-expressors and the wild-type ABCB1 CGC haplotype was associated with slower CL/f and the UGT1A1 *28 genotype wasassociated with increased bilirubin.

TL;DR: Raltegravir's divalent metal ion chelating motif may predispose the drug to interactions with divalent cations, and studies are needed to determine the clinical relevance of this interaction.

TL;DR: An anion exchange isolation of zidovudine triphosphate from human peripheral blood mononuclear cells (hPBMC), coupled with dephosphorylation, desaltation, and detection by liquid chromatography-tandem mass spectroscopy (LC-MS-MS) was validated and correlated well with a previous ELISA method developed and validated in the laboratory.